Novartis scraps Fabhalta study in lupus nephritis

No­var­tis ter­mi­nat­ed a mid-stage tri­al of Fab­hal­ta in lu­pus nephri­tis, cit­ing “strate­gic con­sid­er­a­tions,” ac­cord­ing to a fed­er­al clin­i­cal tri­als data­base.

Fab­hal­ta, al­so known as ip­ta­co­pan …